Sarepta Therapeutics (NASDAQ:SRPT) Given “Buy” Rating at Needham & Company LLC

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “buy” rating restated by analysts at Needham & Company LLC in a research note issued to investors on Monday, Benzinga reports. They currently have a $205.00 price target on the biotechnology company’s stock. Needham & Company LLC’s price target would indicate a potential upside of 64.65% from the stock’s current price.

Other analysts have also recently issued research reports about the stock. Robert W. Baird raised their target price on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, June 21st. UBS Group raised their price objective on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a report on Tuesday, September 17th. Raymond James reiterated an “outperform” rating and set a $150.00 target price on shares of Sarepta Therapeutics in a research note on Thursday. BMO Capital Markets increased their target price on Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a report on Monday, June 24th. Finally, Citigroup decreased their price target on Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating for the company in a report on Thursday, August 8th. Two analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $183.89.

Sarepta Therapeutics Stock Up 1.7 %

Sarepta Therapeutics stock opened at $124.51 on Monday. The firm has a market capitalization of $11.77 billion, a P/E ratio of 1,131.91 and a beta of 0.82. The company has a current ratio of 3.90, a quick ratio of 3.19 and a debt-to-equity ratio of 1.05. Sarepta Therapeutics has a twelve month low of $55.25 and a twelve month high of $173.25. The stock’s fifty day simple moving average is $130.19 and its 200-day simple moving average is $132.51.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.01 by $0.06. The firm had revenue of $362.90 million during the quarter, compared to analysts’ expectations of $394.38 million. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. Sarepta Therapeutics’s revenue for the quarter was up 38.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.27) EPS. As a group, equities analysts expect that Sarepta Therapeutics will post 1.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Michael Andrew Chambers bought 37,038 shares of the firm’s stock in a transaction dated Friday, August 16th. The stock was acquired at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the purchase, the director now owns 284,034 shares of the company’s stock, valued at approximately $38,003,749.20. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Michael Andrew Chambers bought 37,038 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were acquired at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the acquisition, the director now owns 284,034 shares in the company, valued at approximately $38,003,749.20. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in SRPT. Riggs Asset Managment Co. Inc. boosted its holdings in Sarepta Therapeutics by 33.3% in the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 75 shares in the last quarter. GAMMA Investing LLC grew its holdings in Sarepta Therapeutics by 37.0% during the first quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 87 shares during the period. EP Wealth Advisors LLC raised its position in Sarepta Therapeutics by 2.1% in the second quarter. EP Wealth Advisors LLC now owns 4,899 shares of the biotechnology company’s stock worth $774,000 after acquiring an additional 103 shares in the last quarter. Cambridge Investment Research Advisors Inc. lifted its holdings in Sarepta Therapeutics by 1.9% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 6,331 shares of the biotechnology company’s stock valued at $1,000,000 after acquiring an additional 120 shares during the period. Finally, Innealta Capital LLC purchased a new stake in shares of Sarepta Therapeutics during the 2nd quarter worth $31,000. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.